Latest Conference Articles

Novel Agents and Combos Continue to Transform Myeloma Paradigm

Agne Paner, MD, discusses the treatment paradigm in multiple myeloma and promising agents on the horizon.

Analysis Unable to Achieve Concordance Among PD-L1 Assays in TNBC

Mathematical modeling was unable to harmonize the VENTANA SP263 and Dako 22C3 PD-L1 assays with the FDA-approved VENTANA PD-L1 SP142 companion diagnostic for the selection of patients with advanced triple-negative breast cancer appropriate for atezolizumab plus nab-paclitaxel.

Adjuvant Chemo Shows Slight Benefit in Younger Women With Breast Cancer Who Have Mixed Clinical, Genomic Risk

Patients with premenopausal breast cancer and discordant clinical and genomic risk had a small increase in distant metastasis if they did not receive adjuvant chemotherapy, according to a post hoc analysis of the MINDACT trial.

Dr. Rugo on Updated Data From the SOPHIA Trial in HER2+ Metastatic Breast Cancer

Hope S. Rugo, MD, discusses the updated data from the phase III SOPHIA trial for patients with HER2-positive metastatic breast cancer who had received prior anti-HER2 therapies, presented at the 2019 San Antonio Breast Cancer Symposium.

Neoadjuvant Olaparib Combo Safe in Breast Cancer

Adding the PARP inhibitor olaparib to neoadjuvant platinum based-chemotherapy was determined to be a safe treatment for patients with triple-negative breast cancer, as well as for patients with breast cancer whose tumors harbor germline BRCA mutations.

Chemo-Free Regimen Matches Neoadjuvant Chemo in HR+/HER2- Breast Cancer

Almost half of patients with high-risk luminal-B breast cancer converted to a low risk of recurrence following chemotherapy-free neoadjuvant therapy, matching the performance of standard chemotherapy in small randomized trial.

ctDNA and CTCs Potentially Poised to Predict Recurrence for Early TNBC

The presence of circulating tumor DNA and circulating tumor cells following neoadjuvant chemotherapy can be an independent predictor of disease recurrence in patients with early triple-negative breast cancer.

Residual Cancer Burden Predicts Patient Outcomes Across Breast Cancer Subtypes

Residual cancer burden after neoadjuvant chemotherapy has been shown to be an accurate long-term predictor of disease recurrence and survival across all breast cancer subtypes.

Oral Regimen for Paclitaxel Administration May Become Available in Breast Cancer

The addition of encequidar (HM30181A) to oral paclitaxel is the first oral taxane regimen to result in an improvement in overall response rates as compared with an intravenous administration of paclitaxel in patients with metastatic breast cancer.

Estrogen Decreases Breast Cancer Incidence in Postmenopausal Women, Estrogen Plus Progestin Has Opposite Effect

Estrogen alone as menopausal hormone therapy was found to decrease breast cancer incidence in postmenopausal women.

Dr. Pinilla Alba on Safety Findings of the PARTNER Trial in Breast Cancer

Karen Pinilla Alba, MD, discusses the safety findings stages 1 and 2 of the phase II/III PARTNER trial in triple negative and/or germline BRCA-mutated breast cancer.

Neoadjuvant Durvalumab Regimen Shows Promise in TNBC

A durvalumab-based neoadjuvant regimen induced an impressive pathologic complete response rate in patients with triple-negative breast cancer.

Dr. Lin on Impact of Neratinib on CNS Metastases in HER2+ Breast Cancer

Nancy Lin, MD, discusses the impact of neratinib on development and progression of central nervous system metastases in patients with HER2-positive metastatic breast cancer.

Dr. Conte on the OlympiAD Trial in BRCA-Mutated HER2-Negative Breast Cancer

Pierfranco Conte, MD, discusses the findings of the OlympiAD trial in BRCA-mutated HER2-negative metastatic breast cancer.

Accelerated Partial Breast Irradiation Could Replace Whole Breast Irradiation in Low-Risk Early Breast Cancer

Accelerated partial breast irradiation using intensity-modulated radiotherapy is not significantly different from whole breast irradiation in preventing recurrence in patients with low-risk early breast cancer.

Extended Follow-Up Shows Continued Olaparib Benefit in BRCA+ MBC

Olaparib continued to show a numerical overall survival (OS) benefit with a favorable hazard ratio for OS versus chemotherapy in patients with BRCA-positive, HER2-negative metastatic breast cancer, according to an extended, exploratory follow-up analysis of the phase III OlympiAD trial.

Dual Anti-HER2 Therapy Reduces Recurrence Risk

A pathologic complete response to HER2-directed neoadjuvant therapy reduced the risk of recurrence in early HER2-positive breast cancer but did not eliminate it, supporting the common practice of continued anti-HER2 therapy.

Neoadjuvant Atezolizumab Regimen Slightly Improves pCR in TNBC

Atezolizumab (Tecentriq) in combination with carboplatin and nab-paclitaxel (Abraxane) did not lead to a statistically significant increase in pathologic complete response (pCR) rate compared with carboplatin/nab-paclitaxel alone in patients with early high-risk and locally advanced triple-negative breast cancer,

Survival Benefit Hinted at With Durvalumab Maintenance in TNBC

Maintenance durvalumab may improve outcomes versus chemotherapy in patients with triple-negative breast cancer or those with PD-L1–positive breast cancer across several subtypes, according to exploratory analyses from the phase II randomized SAFIR02-IMMUNO trial presented at the 2019 San Antonio Breast Cancer Symposium.

Anastrozole Maintains Breast Cancer Prevention Effect in Long-Term Follow-Up

The aromatase inhibitor anastrozole maintained a preventive effect for postmenopausal women at high risk for breast cancer nearly 12 years after discontinuing treatment.

Benefit in pCR Rates Are Achieved With Pembrolizumab in Early TNBC

Patients with triple-negative breast cancer have greater rates of pathologic complete responses when pembrolizumab is added to neoadjuvant and adjuvant chemotherapy. Furthermore, these benefits are observed across patient subgroups, most notably in those patients with stage III and/or node-positive disease.

Palbociclib Real-World Results Indicate OS Benefit in Frontline HR+/HER2- Breast Cancer

Real-world data for frontline palbociclib indicate that the positive progression-free survival data observed with the CDK4/6 inhibitor in the pivotal PALOMA-2 trial would likely translate to an overall survival benefit in patients with HR-positive/HER2-negative metastatic breast cancer

Dr. Murthy on HER2CLIMB Trial Results in HER2+ Breast Cancer

Rashmi K. Murthy, MD, MBE, discusses results of the HER2CLIMB trial in previously treated HER2-positive breast cancer.

Dr. Hurvitz on Using ADCs in HER2+ Breast Cancer

Sara A. Hurvitz, MD, associate professor of medicine and medical oncologist, University of California Los Angeles, discusses the use of antibody-drug conjugates in HER2-positive breast cancer.

Adjuvant T-DM1 for Early HER2+ Breast Cancer Demonstrates Low Recurrence Rate

The first reported data for adjuvant ado-trastuzumab emtansine in early HER2-positive breast cancer showed high rates of disease control in a randomized trial designed to compare toxicities with trastuzumab and paclitaxel.

Margetuximab Update Elucidates Clinical Benefit in HER2+ Metastatic Breast Cancer

Margetuximab continued to show a clear progression-free survival benefit and a trend toward an overall survival benefit versus trastuzumab (Herceptin) when either agent was combined with chemotherapy in patients with HER2-positive metastatic breast cancer who had received prior anti-HER2 therapies.

Adjuvant Pertuzumab Regimen Shows Modest OS Benefit in HER2+ Early Breast Cancer

Adjuvant pertuzumab (Perjeta) with trastuzumab (Herceptin) plus chemotherapy showed a 0.9% improvement in overall survival and continued to reduce the risk of disease recurrence in patients with HER2-positive early breast cancer.

Tucatinib Boosts Survival in HER2+ Breast Cancer, FDA Submission Imminent

Adding tucatinib to trastuzumab (Herceptin) and capecitabine (Xeloda) reduced the risk of death by 34% in heavily pretreated patients with unresectable locally advanced or metastatic HER2-positive breast cancer.

S-1 Improves iDFS in HR+, HER2- Breast Cancer

Adding the novel oral fluoropyrimidine derivative S-1 to adjuvant endocrine therapy significantly improved invasive disease-free survival for Japanese patients with HR-positive, HER2-negative breast cancer.

T-DXd Shows Potential to Establish New Standard of Care in Advanced HER2+ Breast Cancer

Trastuzumab deruxtecan (T-DXd; DS-8201) induced a confirmed objective response rate of almost 61% and a durable benefit in heavily pretreated patients with advanced HER2-positive breast cancer.